NP10679
Subarachnoid Hemorrhage (SAH)
About NeurOp
NeurOp is a private, clinical-stage biotech leveraging deep expertise in NMDA receptor pharmacology to develop novel treatments for severe CNS conditions. Founded by leading academic neuroscientists from Emory and Duke, the company has advanced its lead compound, NP10679, into Phase 1 trials with initial targets of peri-operative pain and subarachnoid hemorrhage, the latter having received FDA Orphan Drug Designation. NeurOp operates with a lean, advisor-supported model, focusing on precise subunit targeting of the NMDA receptor to improve efficacy and safety over previous non-selective approaches in this challenging target class.
View full company profileAbout NeurOp
NeurOp is a private, clinical-stage biotech leveraging deep expertise in NMDA receptor pharmacology to develop novel treatments for severe CNS conditions. Founded by leading academic neuroscientists from Emory and Duke, the company has advanced its lead compound, NP10679, into Phase 1 trials with initial targets of peri-operative pain and subarachnoid hemorrhage, the latter having received FDA Orphan Drug Designation. NeurOp operates with a lean, advisor-supported model, focusing on precise subunit targeting of the NMDA receptor to improve efficacy and safety over previous non-selective approaches in this challenging target class.
View full company profileTherapeutic Areas
Other Subarachnoid Hemorrhage (SAH) Drugs
| Drug | Company | Phase |
|---|---|---|
| IRRAflow System | IRRAS | Clinical Evaluation |